GleamWall
中文EN

LLY ELI LILLY & Co

Pharmaceutical Preparations · NYSE · SEC CIK 59478 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY45.5%
TTM net income YoY49.8%
TTM EPS YoY50.7%
Revenue 3-yr CAGR39.2%
Net income 3-yr CAGR76.8%

Margins

Gross margin83.6%
Operating margin—
Net margin31.9%
FCF margin—
EBITDA margin—

Returns

ROE86.1%
ROA21.0%
ROIC (approx.)—
Asset turnover0.66x

Leverage & solvency

Liabilities / assets72.8%
Debt / equity1.23x
Current ratio1.39x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.11x
Accruals ratio-2.3%
Payout ratio21.7%
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$24.40B$22.97B$19.80B$19.29B$17.60B$15.56B$12.73B$13.53B
Cost of revenue$3.93B$3.27B$3.58B$3.37B$3.01B$2.45B$2.23B$2.40B
Gross profit$20.46B$19.71B$16.22B$15.92B$14.59B$13.11B$10.50B$11.13B
R&D expense$4.25B$3.82B$3.51B$3.80B$3.47B$3.34B$2.73B$3.02B
SG&A expense$3.12B$3.43B$2.93B$3.13B$2.74B$2.75B$2.47B$2.42B
Interest expense———$222.60M$179.60M$249.00M$243.70M$224.70M
Pretax income$8.41B$9.25B$8.85B$8.27B$7.23B$6.78B$3.46B$5.04B
Income tax$1.96B$2.15B$1.45B$1.63B$1.65B$1.12B$697.00M$628.90M
Net income$6.45B$7.09B$7.40B$6.64B$5.58B$5.66B$2.76B$4.41B
EPS (basic)7.237.958.27—6.226.303.07—
EPS (diluted)7.227.948.26—6.216.293.06—
Dividends declared per share0.003.46—3.230.003.00—2.80
Weighted avg. shares (diluted)893.40M893.70M895.90M—898.80M899.80M900.60M—
Balance sheet
Cash & equivalents$4.88B$8.95B$5.28B$7.27B$9.79B$3.38B$3.09B$3.27B
Short-term investments————$121.60M$170.10M$127.40M$154.80M
Receivables$22.09B$20.08B$18.43B$17.76B$16.11B$14.17B$12.04B$11.01B
Inventory$18.19B$16.79B$14.53B$13.74B$12.18B$11.01B$9.31B$7.59B
Current assets$65.26B$64.67B$54.84B$55.63B$62.07B$49.85B$41.26B$32.74B
PP&E, net$32.19B$29.29B$26.54B$24.68B$22.32B$20.53B$18.47B$17.10B
Goodwill$9.87B$8.85B$6.13B$5.90B$5.90B$5.77B$5.77B$5.77B
Intangibles$18.08B$18.11B$7.37B$6.52B$6.45B$5.91B$6.01B$6.17B
Total assets$148.07B$142.28B$116.58B$112.48B$114.94B$100.92B$89.39B$78.72B
Current liabilities$47.00B$47.74B$36.63B$35.23B$40.14B$39.02B$30.07B$28.38B
Short-term debt$2.52B$7.05B$4.00B$1.64B$1.63B$5.72B$4.02B$5.12B
Long-term debt$46.99B$47.86B$39.37B$40.87B$40.87B$34.18B$34.50B$28.53B
Total debt$49.50B$54.91B$43.37B$42.50B$42.51B$39.90B$38.52B$33.64B
Total liabilities$107.80B$108.40B$85.38B$85.94B$91.08B$82.57B$73.54B$64.44B
Shareholders' equity$40.27B$33.88B$31.20B$26.54B$23.79B$18.27B$15.76B$14.27B
Net debt$44.62B$45.96B$38.09B$35.23B$32.71B$36.53B$35.42B$30.38B
Cash flow statement
Operating cash flow$11.40B$10.69B$5.33B$3.22B$8.84B$3.09B$1.67B$2.47B
Investing cash flow-$8.30B-$15.40B-$3.92B-$2.80B-$2.98B-$1.83B-$3.35B-$1.92B
Financing cash flow-$7.22B$8.43B-$3.47B-$2.88B$531.00M-$1.25B$1.38B-$225.40M
Depreciation & amortization$545.00M$534.00M$509.00M$586.00M$470.00M$478.00M$463.00M$484.80M
Stock-based compensation$200.00M$201.00M$161.00M$136.10M$151.00M$185.00M$154.00M$141.90M
Dividends paid$1.54B$1.55B$1.55B$1.35B$1.35B$1.35B$1.35B$1.17B
Share buybacks$377.00M$1.60B$2.36B$1.51B$708.00M$692.20M$1.20B$2.05B

Free plan shows the latest 8 periods; Pro shows all 74 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.